BlueWillow Biologics®, a clinical-stage biopharmaceutical company, today announced the U.S. Food and Drug Administration (FDA) has cleared its investigational new drug (IND) application for BW-1010, the company’s next-generation anthrax vaccine candidate. The Phase 1 clinical study is expected to begin enrollment this year and is being funded by the National Institute of Allergy and Infectious … Continued
The American Academy of Physical Medicine and Rehabilitation (AAPM&R) has selected ArborMetrix as its partner for a new, state-of-the-art physiatry clinical data registry. The registry will advance AAPM&R’s ability to collect high-quality, clinician and patient data across independent physician practices and larger institutions for use in generating insights to inform best practices, guide pioneering research, and … Continued
Blue Medora, the leading provider of enterprise IT monitoring integration solutions, announced today that the Company’s Board of Directors has appointed Bekim Protopapa as President and Chief Executive Officer. He will assume day-to-day leadership of the Company and will also join Blue Medora’s Board of Directors. Bekim is a highly experienced senior executive, having spent … Continued
BlueWillow Biologics®, a clinical-stage biopharmaceutical company, today announced it has been awarded a Fast-Track Small Business Research Innovation (SBIR) contract from the National Institute of Allergy and Infectious Diseases (NIAID) for the development of an intranasal therapeutic peanut allergy vaccine using the company’s NanoVax® platform. Pending approval of all phases, the contract will provide funding … Continued